Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Lung Cancer | Research article

The correlation between skeletal muscle index of the L3 vertebral body and malnutrition in patients with advanced lung cancer

Authors: Xiangliang Liu, Wei Ji, Kaiwen Zheng, Jin Lu, Lingyu Li, Jiuwei Cui, Wei Li

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Studies have shown that the skeletal muscle index at the third lumbar vertebra (L3 SMI) had reasonable specificity and sensitivity in nutritional assessment and prognostic prediction in digestive system cancers, but its performance in lung cancer needs further investigation.

Methods

A retrospective study was performed on 110 patients with advanced lung cancer. The L3 SMI, the Patient-Generated Subjective Global Assessment score (PG-SGA score), body mass index (BMI), and serological indicators were analyzed. According to PG-SGA scores, patients were divided into severe malnutrition (≥9 points), mild to moderate malnutrition (≥3 points and ≤ 8 points), and no malnutrition (≤2 points) groups. Pearson correlation and logistic regression analysis were adopted to find factors related to malnutrition, and a forest plot was drawn. The receiver operating characteristic (ROC) curve was performed to compare the diagnostic values of malnutrition among factors, which were expressed by the area under curve (AUC).

Results

1. The age of patients in the severe malnutrition group, the mild to moderate malnutrition group, and the no malnutrition group significantly differed, with mean ages of 63.46 ± 10.01 years, 60.42 ± 8.76 years, and 55.03 ± 10.40 years, respectively (OR = 1.062, 95%CI: 1.008 ~ 1.118, P = 0.024; OR = 1.100, 95%CI: 1.034 ~ 1.170, P = 0.002). Furthermore, the neutrophil to lymphocyte ratio (NLR) of the severe malnutrition group was significantly higher than that of the no malnutrition group, with statistical significance. The difference between the mild to moderate malnutrition group and the no malnutrition group were not statistically significant, with NLR of 4.07 ± 3.34 and 2.47 ± 0.92, respectively (OR = 1.657,95%CI: 1.036 ~ 2.649, P = 0.035). The L3 SMI of patients in the severe malnutrition and mild to moderate malnutrition groups were significantly lower than that of the patients in the no malnutrition group, with statistical significance. The L3 SMI of patients in the severe malnutrition group, mild to moderate malnutrition group, and no malnutrition group were 27.40 ± 4.25 cm²/m², 38.19 ± 6.17 cm²/m², and 47.96 ± 5.02 cm²/m², respectively (OR = 0.600, 95%CI: 0.462 ~ 0.777, P < 0.001; OR = 0.431, 95%CI: 0.320 ~ 0.581, P < 0.001).

2. The Pearson correlation analysis showed that the PG-SGA score positively correlated with age (r = 0.296, P < 0.05) but negatively correlated with L3 SMI (r = − 0.857, P < 0.05). The L3 SMI was also negatively correlated with age (r = − 0.240, P < 0.05).

3. The multivariate analysis showed that the L3 SMI was an independent risk factor for malnutrition (OR = 0.446, 95%CI: 0.258 ~ 0.773, P = 0.004; OR = 0.289, 95%CI: 0.159 ~ 0.524, P < 0.001).

Conclusion

1. The differences in the L3 SMI was statistically significant among advanced lung cancer patients with different nutritional statuses.

2. In the nutritional assessment of patients with lung cancer, the L3 SMI was consistent with the PG-SGA.

3. The L3 SMI is an independent predictor of malnutrition in patients with advanced lung cancer.

Duan JJ, Yan YQ, Yang N, et al. International Comparative Analysis of the Incidence and Mortality of Malignant Tumors in China [J]. Chin J Front Med (Electronic Edition). 2016;8(7):17–23. https://doi.org/10.3969/j.issn.1674-7372.2016.07.005.CrossRef

Wu BW, Yin T, Cao WX, Gu ZD, Wang XJ, Yan M, et al. Clinical application of subjective global assessment in Chinese patients with gastrointestinal cancer. World J Gastroenterol. 2009;15(28):3542–9. https://doi.org/10.3748/wjg.15.3542.CrossRefPubMedPubMedCentral

Ramos Chaves M, Boléo-Tomé C, Monteiro-Grillo I, Camilo M, Ravasco P. The diversity of nutritional status in cancer: new insights. Oncologist. 2010;15(5):523–30. https://doi.org/10.1634/theoncologist.2009-0283.CrossRefPubMedPubMedCentral

Righini CA, Timi N, June P, Bertolo A, Reyt E, Atallah I. Assessment of nutritional status at the time of diagnosis in patients treated for head and neck cancer. Eur Ann Otorhinolaryngol Head Neck Dis. 2013;130(1):8–14. https://doi.org/10.1016/j.anorl.2012.10.001.CrossRefPubMed

Khalid U, Spiro A, Baldwin C, Sharma B, McGough C, Norman AR, et al. Symptoms and weight loss in patients with gastrointestinal and lung cancer at presentation. Support Care Cancer. 2007;15(1):39–46. https://doi.org/10.1007/s00520-006-0091-0.CrossRefPubMed

Hébuterne X, Lemarié E, Michallet M, de Montreuil CB, Schneider SM, Goldwasser F. Prevalence of malnutrition and current use of nutrition support in patients with cancer. JPEN J Parenter Enteral Nutr. 2014;38(2):196–204. https://doi.org/10.1177/0148607113502674.CrossRefPubMed

Marshall KM, Loeliger J, Nolte L, Kelaart A, Kiss NK. Prevalence of malnutrition and impact on clinical outcomes in cancer services: a comparison of two time points. Clin Nutr. 2019;38(2):644–51. https://doi.org/10.1016/j.clnu.2018.04.007.CrossRefPubMed

Cederholm T, Barazzoni R, Austin P, Ballmer P, Biolo G, Bischoff SC, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr. 2017;36(1):49–64. https://doi.org/10.1016/j.clnu.2016.09.004.CrossRefPubMed

Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing. 2010;39(4):412–23. https://doi.org/10.1093/ageing/afq034.CrossRefPubMedPubMedCentral

10.

Ikizler TA, Cano NJ, Franch H, et al. Prevention and treatment of protein-energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism. Kidney Int. 2013;84(6):1096–107. https://doi.org/10.1038/ki.2013.147.CrossRefPubMed

11.

Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9(7):629–35. https://doi.org/10.1016/S1470-2045(08)70153-0.CrossRefPubMed

12.

Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31(12):1539–47. https://doi.org/10.1200/JCO.2012.45.2722.CrossRefPubMed

13.

Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer. 2016;57:58–67. https://doi.org/10.1016/j.ejca.2015.12.030.CrossRefPubMed

14.

Barret M, Antoun S, Dalban C, Malka D, Mansourbakht T, Zaanan A, et al. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer. 2014;66(4):583–9. https://doi.org/10.1080/01635581.2014.894103.CrossRefPubMed

15.

Zheng ZF, Lu J, Xie JW, Wang JB, Lin JX, Chen QY, et al. Preoperative skeletal muscle index vs the controlling nutritional status score: which is a better objective predictor of long-term survival for gastric cancer patients after radical gastrectomy? Cancer Med. 2018;7(8):3537–47. https://doi.org/10.1002/cam4.1548.CrossRefPubMedPubMedCentral

16.

Wagner D, DeMarco MM, Amini N, Buttner S, Segev D, Gani F, et al. Role of frailty and sarcopenia in predicting outcomes among patients undergoing gastrointestinal surgery. World J Gastrointest Surg. 2016;8(1):27–40. https://doi.org/10.4240/wjgs.v8.i1.27.CrossRefPubMedPubMedCentral

17.

Kim HJ, Kim HJ, Yun J, Kim KH, Kim SH, Lee SC, et al. Pathophysiological role of hormones and cytokines in cancer cachexia. J Korean Med Sci. 2012;27(2):128–34. https://doi.org/10.3346/jkms.2012.27.2.128.CrossRefPubMedPubMedCentral

18.

Longhua H, Furong C, Yan H. Enteral nutrition treatment impact on immune function and intestine function recovery for the patients with gastric carcinoma[J]. Modern Oncol. 2016;24(13):2119–22.

19.

Shi YY, Zhang XW, Yuan KT, et al. SOP of PG-SGA. Chinese journal of Cancer prevention and treatment[J]. Chin J Cancer Prevent Treat. 2013;20(22):1779–82.

20.

Poziomyck AK, Weston AC, Lameu EB, Cassol OS, Coelho LJ, Moreira LF. Preoperative nutritional assessment and prognosis in patients with foregut tumors. Nutr Cancer. 2012;64(8):1174–81. https://doi.org/10.1080/01635581.2012.721157.CrossRefPubMed

21.

Bauer J, Capra S, Ferguson M. Use of the scored patient-generated subjective global assessment (PG-SGA) as a nutrition assessment tool in patients with cancer. Eur J Clin Nutr. 2002;56(8):779–85. https://doi.org/10.1038/SJ.ejcn.1601412.CrossRefPubMed

22.

Kao SC, Pavlakis N, Harvie R, et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res. 2010;16(23):5805–13. https://doi.org/10.1158/1078-0432.CCR-10-2245.CrossRefPubMed

23.

Miyamoto R, Inagawa S, Sano N, Tadano S, Yamamoto M. Neutrophil-to-lymphocyte ratio(NLR) to predict the short-term and long-term outcomes of gastric cancer patients. J Clin Oncol. 2017;35(15_suppl):e15560. https://doi.org/10.1200/JCO.2017.35.15_suppl.e15560.CrossRef

24.

Singh R, Mishra MK, Aggarwal H. Inflammation, immunity, and Cancer. Mediat Inflamm. 2017;2017:6027305. https://doi.org/10.1155/2017/6027305.CrossRef

25.

Volpi E, Sheffield-Moore M, Rasmussen BB, Wolfe RR. Basal muscle amino acid kinetics and protein synthesis in healthy young and older men. JAMA. 2001;286(10):1206–12. https://doi.org/10.1001/jama.286.10.1206.CrossRefPubMedPubMedCentral

26.

Visser M, Deeg DJ, Lips P, longitudinal aging study Amsterdam. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the longitudinal aging study Amsterdam. J Clin Endocrinol Metab. 2003;88(12):5766–72. https://doi.org/10.1210/jc.2003-030604.CrossRefPubMed

27.

Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis [published correction appears in age ageing. 2019 Jul 1;48(4):601]. Age Ageing. 2019;48(1):16–31. https://doi.org/10.1093/ageing/afy169.CrossRefPubMed

28.

Schweitzer L, Geisler C, Pourhassan M, Braun W, Glüer CC, Bosy-Westphal A, et al. What is the best reference site for a single MRI slice to assess whole-body skeletal muscle and adipose tissue volumes in healthy adults? Am J Clin Nutr. 2015;102(1):58–65. https://doi.org/10.3945/ajcn.115.111203.CrossRefPubMed

29.

Taguchi S, Akamatsu N, Nakagawa T, Gonoi W, Kanatani A, Miyazaki H, et al. Sarcopenia evaluated using the skeletal muscle index is a significant prognostic factor for metastatic Urothelial carcinoma. Clin Genitourin Cancer. 2016;14(3):237–43. https://doi.org/10.1016/j.clgc.2015.07.015.CrossRefPubMed

30.

Segura A, Pardo J, Jara C, Zugazabeitia L, Carulla J, de las Peñas R, et al. An epidemiological evaluation of the prevalence of malnutrition in Spanish patients with locally advanced or metastatic cancer. Clin Nutr. 2005;24(5):801–14. https://doi.org/10.1016/j.clnu.2005.05.001.CrossRefPubMed

31.

Sánchez-Lara K, Ugalde-Morales E, Motola-Kuba D, Green D. Gastrointestinal symptoms and weight loss in cancer patients receiving chemotherapy. Br J Nutr. 2013;109(5):894–7. https://doi.org/10.1017/S0007114512002073.CrossRefPubMed

32.

Ravasco P, Monteiro-Grillo I, Marques Vidal P, Camilo ME. Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. Head Neck. 2005;27(8):659–68. https://doi.org/10.1002/hed.20221.CrossRefPubMed

33.

Bovio G, Montagna G, Bariani C, Baiardi P. Upper gastrointestinal symptoms in patients with advanced cancer: relationship to nutritional and performance status. Support Care Cancer. 2009;17(10):1317–24. https://doi.org/10.1007/s00520-009-0590-x.CrossRefPubMed

34.

Cao DX, Wu GH, Zhang B, Quan YJ, Wei J, Jin H, et al. Resting energy expenditure and body composition in patients with newly detected cancer. Clin Nutr. 2010;29(1):72–7. https://doi.org/10.1016/j.clnu.2009.07.001.CrossRefPubMed

35.

Shaw C, Fleuret C, Pickard JM, Mohammed K, Black G, Wedlake L. Comparison of a novel, simple nutrition screening tool for adult oncology inpatients and the malnutrition screening tool (MST) against the patient-generated subjective global assessment (PG-SGA). Support Care Cancer. 2015;23(1):47–54. https://doi.org/10.1007/s00520-014-2319-8.CrossRefPubMed

36.

Matsunaga T, Saito H, Murakami Y, Kuroda H, Fukumoto Y, Osaki T. Serum level of C-reactive protein on postoperative day 3 is a predictive indicator of postoperative pancreatic fistula after laparoscopic gastrectomy for gastric cancer. Asian J Endosc Surg. 2017;10(4):382–7. https://doi.org/10.1111/ases.12374.CrossRefPubMed

37.

Roch B, Coffy A, Jean-Baptiste S, Palaysi E, Daures JP, Pujol JL, et al. Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors. Lung Cancer. 2020;143:19–26. https://doi.org/10.1016/j.lungcan.2020.03.003.CrossRefPubMed

38.

Meng SJ, Yu LJ. Oxidative stress, molecular inflammation and sarcopenia. Int J Mol Sci. 2010;11(4):1509–26. Published 2010 Apr 12. https://doi.org/10.3390/ijms11041509.CrossRefPubMedPubMedCentral

Title: The correlation between skeletal muscle index of the L3 vertebral body and malnutrition in patients with advanced lung cancer
Authors: Xiangliang Liu
Wei Ji
Kaiwen Zheng
Jin Lu
Lingyu Li
Jiuwei Cui
Wei Li
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Lung Cancer
Lung Cancer
Nutrition
Malnutrition
Lung Cancer
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08876-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Association between heavy metals and colon cancer: an ecological study based on geographical information systems in North-Eastern Iran

Optimizing oropharyngeal cancer management by using proton beam therapy: trends of cost-effectiveness

Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment

Intensity of end-of-life health care and mortality after systemic anti-cancer treatment in patients with advanced lung cancer

Optimal margins for early stage peripheral lung adenocarcinoma resection

Associations between I/D polymorphism in the ACE gene and lung cancer: an updated systematic review and a meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer